ESMO 2026 | Who can benefit more from 1L pembrolizumab in dMMR endometrial cancer?
Brian Slomovitz, MD, Mount Sinai Comprehensive Cancer Center, Miami, FL, discusses the limitations of KEYNOTE-C93/GOG-3064/ENGOT-en15 study (NCT05173987) comparing a first-line pembrolizumab to chemotherapy alone in in mismatch repair-deficient (dMMR) advanced or recurrent endometrial carcinoma. While the results will not immediately replace the current standard of chemotherapy plus immunotherapy, the study did show improvement in progression-free survival, duration of response, and quality of life. The investigational regimen may be an option for patients prioritizing a chemotherapy-free treatment with reduced side effects. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
